OR WAIT null SECS
Metagenomi has successfully raised $175 million for use toward its research pipeline.
Metagenomi, a gene editing start-up focused on metagenomics, announced that they have secured $175 million in funding. In addition to past funding, this gives the start-up approximately $300 million to spend toward its gene editing therapeutic programs, the company stated in a Jan. 25, 2021 press release.
Metagenomi uses a metagenomics-powered platform to develop potentially curative therapeutics to accurately edit DNA where current technologies struggle. This recent financing will go towards funding their lead in-vivo and ex-vivo gene-editing therapeutic programs
“Our expertise in mining the world’s natural environments for novel gene editing systems has resulted in the discovery of a powerful suite of gene editing tools,” said Brian C. Thomas, co-founder and CEO of Metagenomi, in the press release. “We are honored to be supported by an impressive group of investors who understand the enormous potential of our gene editing capabilities. We look forward to the next phase of the [c]ompany’s development as we accelerate our lead gene editing programs and open new treatment options in metabolic, cardiovascular, and CNS diseases as well as in immuno-oncology.”
In November 2021, Metagenomi struck a deal with Moderna to investigate genetic medicines for various unspecified diseases.